<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sylvester, Bruce</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kapur, Akhil</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PCI is a “Reasonable” Strategy for Diabetic Patients with Multivessel Disease: The CARDia Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">At 1 year following intervention, there apparently is no difference between coronary artery bypass grafting and percutaneous coronary intervention in treating diabetic patients with multivessel disease, as measured by the incidence of a composite of death, myocardial infarction, and stroke. These results are part of the Coronary Artery Revascularization in Diabetes [CARDia; ISRCTN19872154] trial.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>